Nanovi submits cancer biomarker for marketing approval in the US
Danish firm Nanovi has submitted its leading product, a biomarker for cancer therapies, for approval on the world’s biggest cancer market, where it has the potential to break new ground, says CEO Jesper Boysen.
by albert rønning-andersson, translated by daniel pedersen
Danish medtech firm Nanovi, whose chair of the board is Ambu heir Simon Hesse Hoffmann, has reached one of the bigger milestones in its history, which began in 2012 when the company was spun out from the Technical University of Denmark, DTU.
An HR expert points to increasing competition for skilled workers combined with their pandemic fatigue as factors behind initiatives like Novo Nordisk’s advanced salary talks, Genmab’s extra day off a month, and Bavarian Nordic’s gift of four vacation days.